Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
17 avr. 2019 09h05 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
12 mars 2019 09h00 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
26 nov. 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc Reports Third Quarter 2018 Results
07 nov. 2018 16h15 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada
30 oct. 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage
02 oct. 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018
17 sept. 2018 17h00 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial
27 août 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018
01 août 2018 08h00 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers
11 juil. 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., July 11, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...